Biotech Values

[DewDiligence]

In 2007 when MNTA received the request from the FDA for more immunogenicity data, did TEVA voluntarily disclose that they received that request as well?

Teva didn’t get to decide whether to reveal or hide the FDA’s 2007 request for immunogenicity data because MNTA spilled the beans on its 11/6/07 CC: #msg-24437833.

Just wondering – if TEVA were asked to provide more information now regarding their ANDA that would cause a significant delay, if they would disclose this information or not.

The answer depends on the nature of the request and how significant the delay was expected to be. Although it’s in Teva’s interests to please its own shareholders by being transparent about Lovenox, it’s also in Teva’s interests to undermine MNTA by being opaque.

From an economic standpoint, Teva has relatively little to gain from its own success with Lovenox, but it has an enormous amount to lose from MNTA’s success with Copaxone. Thus, anything Teva can do to undermine MNTA’s corporate success generally becomes an attractive undertaking.